Revelation Biosciences, Inc. announced its financial results for the three and six months ended June 30, 2025. The company reported a net loss of $2.4 million for the second quarter of 2025, a significant improvement from the $8.4 million net loss in Q2 2024. For the six months ended June 30, 2025, the net loss was $4.5 million, compared to $11.1 million in the prior year.
As of June 30, 2025, Revelation held $5.2 million in cash and cash equivalents, a decrease from $6.5 million at December 31, 2024. Net cash used in operating activities for the quarter was $4.7 million, compared to $5.3 million for the same period in 2024. The company projects its current cash and cash equivalents are sufficient to fund operations through December 2025.
CEO James Rolke stated that the company continues to strategically maximize its financial resources to advance the Gemini program. He expressed anticipation for announcing data from the Phase 1b study later in the current quarter and engaging with the FDA later this year to further the clinical development of Gemini. Research and development expenses for Q2 2025 were $1,317,980, while general and administrative expenses were $1,143,249.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.